Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
11 oct. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
27 sept. 2018 16h01 HE
|
Spero Therapeutics, Inc.
Multiple ascending dose clinical data supports advancement of 600 mg TID dose for pivotal Phase 3 clinical trial, planned for initiation around year-end 2018600 mg dose provides greater drug exposure...
Spero Therapeutics Announces Presentations at IDWeek 2018
25 sept. 2018 16h01 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October
19 sept. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
28 août 2018 08h00 HE
|
Spero Therapeutics, Inc.
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology ...
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors
14 août 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
09 août 2018 16h10 HE
|
Spero Therapeutics, Inc.
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-endRecent Follow-on Offering and BARDA...
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
16 juil. 2018 06h59 HE
|
Spero Therapeutics, Inc.
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...
Spero Therapeutics Announces Pricing of Securities Offering
12 juil. 2018 20h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Proposed Offering of Common Stock
09 juil. 2018 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...